<SEC-DOCUMENT>0000078003-15-000022.txt : 20150501
<SEC-HEADER>0000078003-15-000022.hdr.sgml : 20150501
<ACCEPTANCE-DATETIME>20150501163124
ACCESSION NUMBER:		0000078003-15-000022
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20150501
DATE AS OF CHANGE:		20150501

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida Corp.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-81613
		FILM NUMBER:		15824781

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>pf13daps.htm
<DESCRIPTION>SCHEDULE 13D AMENDMENT
<TEXT>
<html>
<head>
<title>Schedule 13DA</title>
</head>

<body bgcolor="#FFFFFF" text="#000000">
<p align="center"> <br>
  <b>UNITED STATES <br>
  SECURITIES AND EXCHANGE COMMISSION <br>
  Washington, D.C. 20549</b><br>
  <br>
  <b>SCHEDULE 13D<br>
  Under the Securities Exchange Act of 1934<br>
  (Amendment No. 1)*</b><br>
  <br>
  <strong>PSIVIDA CORP.</strong><br>
  (Name of Issuer)</p>
<p align="center"><strong>Common Stock, par value $0.001 per share</strong><br>
  (Title of Class of Securities)</p>
<p align="center"><strong>74440J101</strong><br>
  (CUSIP Number)</p>
<p align="center"><strong>Margaret M. Madden, Esq.</strong><strong> </strong><br>
  <strong>Vice  President and Corporate Secretary, </strong><br>
  <strong>Chief  Governance Counsel<br>
  Pfizer Inc.<br>
    235 East 42nd Street<br>
    New York, New York 10017<br>
(212) 733-2323</strong></p>
<p align="center">(Name, Address and Telephone Number of Person <br>
  Authorized to Receive Notices and Communications)</p>
<p align="center"><strong>January 24, 2011</strong></p>
<p align="center">(Date of Event which Requires Filing of this Statement)</p>
<p align="left">&nbsp;</p>
<p>If the filing person has previously filed  a statement on Schedule 13G to report the acquisition that is the subject of  this Schedule 13D, and is filing this schedule because of &sect;&sect; 240.13d-1(e),  240.13d-1(f) or 240.13d-1(g), check the following box. |_|<br>
  &nbsp; <br>
  <strong>Note:</strong>&nbsp; Schedules filed in  paper format shall include a signed original and five copies of the schedule,  including all exhibits.&nbsp; See &sect; 240.13d-7  for other parties to whom copies are to be sent. <br>
  &nbsp; <br>
  *The remainder of this cover page shall be  filled out for a reporting person&rsquo;s initial filing on this form with respect to  the subject class of securities, and for any subsequent amendment containing  information which would alter the disclosures provided in a prior cover page.  &nbsp; </p>
The information required on the remainder of this  cover page shall not be deemed to be &ldquo;filed&rdquo; for the purpose of Section 18 of  the Securities Exchange Act of 1934 (&ldquo;Act&rdquo;) or otherwise subject to the  liabilities of that section of the Act but shall be subject to all other  provisions of the Act (however, see the Notes).
<p align="left">&nbsp;</p>
CUSIP No.  <strong>74440J101</strong>&nbsp; <br>
<br>
1. Names of Reporting Persons IRS Identification Nos. of above persons (entities
only)<br>
Pfizer Inc. &nbsp;13-5315170<br>
<br>
2. Check the Appropriate Box if a Member of a Group (See Instructions)<br>
<br>
(a) <br>
<br>
(b) <br>
<br>
3. SEC Use Only ........................................................................................
<br>
<br>
4. Source of Funds (See Instructions) &nbsp;&nbsp;WC<br>
<br>
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d)
or 2(e) <br>
<br>
6. Citizenship or Place of Organization Delaware
<p>&nbsp;</p>
<table width="83%" border="0">
  <tr>
    <td rowspan="4" width="24%">
      <div align="center">
        <p align="left">NUMBER OF<br>
          <br>
          SHARES<br>
          <br>
          BENEFICIALLY </p>
        <p align="left">OWNED BY EACH REPORTING</p>
        <p align="left"> PERSON WITH<br>
        </p>
      </div>
    </td>
    <td width="63%" height="47">7. Sole Voting Power &nbsp;&nbsp;&nbsp;1,862,093</td>
  </tr>
  <tr>
    <td width="63%" height="43">8. Shared Voting Power &nbsp;&nbsp;0</td>
  </tr>
  <tr>
    <td width="63%" height="53">9. Sole Dispositive Power 1,862,093</td>
  </tr>
  <tr>
    <td width="63%" height="60">10. Shared Dispositive Power &nbsp;&nbsp;0</td>
  </tr>
</table>
<p>11. Aggregate Amount Beneficially Owned by Each Reporting Person&nbsp;&nbsp;1,862,093<br>
  <br>
  12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |_|<br>
  <br>
  13. Percent of Class Represented by Amount in Row (11) &nbsp;&nbsp;6.3%<br>
  <br>
14. Type of Reporting Person (See Instructions) CO</p>
<p>This Amendment No. 1 (this &ldquo;Amendment&rdquo;) amends  and supplements the statement on Schedule 13D originally filed by Pfizer Inc. (&ldquo;Pfizer&rdquo;)  with the U.S. Securities and Exchange Commission on July 16, 2007 (the &ldquo;Schedule  13D&rdquo;) and relates to the common stock, par value $0.001 per share (&ldquo;Common  Stock&rdquo;), of pSivida Corp. (the &ldquo;Issuer&rdquo;). This Amendment is being filed to update  the percentage of Common Stock of the Issuer beneficially owned by Pfizer as a  result of dilution due to equity issuances by the Issuer. &nbsp;Except as specifically provided herein, this  Amendment does not modify any of the information previously reported on the  Schedule 13D.&nbsp; Unless otherwise  indicated, each capitalized term used but not defined herein shall have the meaning  assigned to such term in the Schedule 13D. <strong></strong></p>
<p><strong>Item 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Identity and Background</strong></p>
<p>Item  2 is hereby amended and supplemented as follows:<strong> </strong></p>
<p>This Amendment is filed on behalf of  Pfizer, a Delaware corporation.&nbsp; Pfizer is  a research-based, global pharmaceutical company.&nbsp; The principal address of Pfizer is 235 East  42nd Street, New York, New York 10017. </p>
<p>Set forth on Schedule A hereto, which is  incorporated herein by reference, is the name, business address, principal  occupation or employment and the name, principal business and address of any  corporation or other organization in which such employment is conducted and  citizenship of each of Pfizer&rsquo;s directors and executive officers. </p>
<p>During the past five years, neither Pfizer,  nor, to its knowledge, any of Pfizer&rsquo;s directors or executive officers, has  been (i) convicted in a criminal proceeding (excluding traffic violations and similar  misdemeanors), or (ii) a party to a civil proceeding of a judicial or administrative  body of competent jurisdiction and as a result of such proceeding was or is  subject to a judgment, decree or final order enjoining future violations of, or  prohibiting or mandating activities subject to, federal or state securities  laws or finding any violation with respect to such laws.</p>
<p><strong>Item 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purpose  of the Transaction</strong></p>
<p>Item  4 is hereby amended and supplemented as follows:</p>
<p>Pfizer acquired the shares of Common Stock  reported on this schedule for investment purposes, and such investment was made  in Pfizer&rsquo;s ordinary course of business. In pursuing such investment purposes, Pfizer  may further purchase, hold, vote, trade, dispose or otherwise deal in the  Common Stock at times, and in such manner (including pursuant to hedging  transactions), as it deems advisable to benefit from changes in market prices  of the Common Stock, changes in the Issuer&rsquo;s operations, business strategy or  prospects, or from a sale or merger of the Issuer. To evaluate such  alternatives, Pfizer routinely will monitor the Issuer&rsquo;s operations, prospects,  business development, management, competitive and strategic matters, capital  structure, and prevailing market conditions, as well as alternative investment  opportunities, Pfizer&rsquo;s liquidity requirements, and other investment  considerations. Consistent with its investment research methods and evaluation  criteria, Pfizer may discuss such matters with management or directors of the  Issuer, other shareholders, industry analysts, existing or potential strategic  partners or competitors, investment and financing professionals, sources of  credit, and other investors. Such factors and discussions may materially affect,  and result in, Pfizer modifying its ownership of the Common Stock, exchanging  information with the Issuer pursuant to appropriate confidentiality or similar  agreements, proposing changes in the Issuer&rsquo;s operations, governance or  capitalization, or in proposing one or more of the other actions described in  paragraphs (a) through (j) of Item 4 of Schedule 13D. Pfizer reserves the right  to formulate other plans and/or make other proposals and take such actions with  respect to its investment in the Issuer, including any or all of the actions  set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D, or acquire  additional Common Stock or dispose of all Common Stock held by it, in public  market or privately negotiated transactions. Pfizer may at any time reconsider  and change its plans or proposals relating to the foregoing.</p>
<p><strong>Item 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interest in Securities of the Issuer<br>
  </strong><br>
  Item 5 is  hereby amended and supplemented as follows:</p>
<p><strong>(a) </strong>The  information set forth on the cover pages to this Amendment is incorporated  herein by reference. </p>
<p><strong>(b) </strong>The  information set forth on the cover pages to this Amendment is incorporated  herein by reference. <br>
  <br>
  <strong>(c) </strong>Pfizer  has not engaged in any transactions with respect to the Issuer&rsquo;s Common Stock  in the past 60 days.<br>
  <br>
  <strong>(d) </strong>Not applicable.<br>
  <br>
  <strong>(e) </strong>Not applicable.</p>
<p>Pursuant to a reincorporation from Australia to  Delaware, United States effected by the Issuer in June 2008, Pfizer received  one share of the Issuer&rsquo;s common stock for every forty (40) ordinary shares  held in pSivida Limited, the Issuer&rsquo;s predecessor entity. Pfizer has not  transacted in the Issuer&rsquo;s or its predecessor&rsquo;s equity securities since the  filing of the Schedule 13D.&nbsp; </p>
<p>As a result primarily of offerings of Common Stock by  the Issuer to certain institutional investors completed in January 2011, August  2012 and March 2014, and an underwritten public offering completed in July 2013,  Pfizer&rsquo;s ownership in the Issuer as reported on the Schedule 13D has been  diluted. </p>
<p>The ownership percentage set forth in Row 11 of the  cover page hereto has been calculated based on an assumed total of 29,412,365  shares of Common Stock outstanding as of February 3, 2015, as reported in the Issuer&rsquo;s  Quarterly Report on Form 10-Q for the quarter ended December 31, 2014.</p>
<p>&nbsp;</p>
<p align="center"><br>
  <i><b>Signature</b></i></p>
<p>After reasonable inquiry and to the best of my knowledge and  belief, I certify that the information set forth in this statement is true,  complete and correct.<br>
  &nbsp;</p>
<p align="left">  Dated: May 1, 2015</p>
<p align="left">Pfizer Inc. </p>
<p>By: <u>/s/ Susan Grant</u><br>
  Name: Susan Grant
  <br>
  Title:&nbsp;Assistant Secretary,
  Pfizer Inc. <br>
</p>
<p align="center">&nbsp;</p>
<hr width="100%" noshade size=4>
<p>&nbsp;</p>
<p align="right"><strong>Schedule A</strong></p>
<p align="center">DIRECTORS AND  EXECUTIVE OFFICERS OF  PFIZER INC. </p>
<p>Set forth below is the name,  business address and present occupation or employment of each director and executive  officer of Pfizer Inc. Except as indicated  below, each such person is a citizen of the United States.</p>
<blockquote>
  <blockquote>
    <blockquote>
      <blockquote>
        <blockquote>
          <p align="left"><strong>DIRECTORS OF  PFIZER INC.</strong><strong> </strong></p>
        </blockquote>
      </blockquote>
    </blockquote>
  </blockquote>
</blockquote>
<table border="1" cellspacing="0" cellpadding="0" width="656">
  <tr>
    <td width="187" valign="bottom"><p align="center"><strong>NAME</strong></p></td>
    <td width="294" valign="bottom"><p align="center"><strong>PRINCIPAL    OCCUPATION</strong><br>
      <strong>OR    EMPLOYMENT</strong></p></td>
    <td width="175" valign="bottom"><p align="center"><strong>ADDRESS</strong></p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Dennis A. Ausiello </p></td>
    <td width="294" valign="top"><p>Director &ndash; Center of    Assessment Technology and Continuous Health (CATCH)<br>
      Physician-in-Emeritus &ndash; Massachusetts    General Hospital </p></td>
    <td width="175" valign="top"><p>c/o Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>W. Don Cornwell </p></td>
    <td width="294" valign="top"><p>Founder and Retired    Chairman and CEO &ndash; Granite Broadcasting Corporation</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Frances D. Fergusson </p></td>
    <td width="294" valign="top"><p>President Emeritus &ndash; Vassar    College</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Helen H. Hobbs </p></td>
    <td width="294" valign="top"><p>Investigator &ndash; Howard    Hughes Medical Institute </p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>James M. Kilts </p></td>
    <td width="294" valign="top"><p>Founding Partner &ndash; Centerview    Capital</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Shantanu Narayen</p></td>
    <td width="294" valign="top"><p>President and CEO &ndash; Adobe    Systems Inc.</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Suzanne Nora Johnson</p></td>
    <td width="294" valign="top"><p>Former Vice Chairman &ndash; The    Goldman Sachs Group, Inc.</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Ian C. Read</p></td>
    <td width="294" valign="top"><p>Chairman and CEO &ndash; Pfizer    Inc.</p></td>
    <td width="175" valign="top"><p>Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Stephen W. Sanger</p></td>
    <td width="294" valign="top"><p>Retired Chairman and CEO &ndash;    General Mills Inc.</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>James C. Smith</p></td>
    <td width="294" valign="top"><p>CEO &ndash; Thomson Reuters</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Marc Tessier-Lavigne</p></td>
    <td width="294" valign="top"><p>President &ndash; The    Rockefeller University</p></td>
    <td width="175" valign="top"><p>c/o    Pfizer Inc.<br>
      235 East 42nd Street<br>
      New York, NY&nbsp; 10017 </p></td>
  </tr>
</table>
<p align="center"><strong>&nbsp;</strong></p>
<blockquote>
  <blockquote>
    <blockquote>
      <blockquote>
        <p align="left"><strong>EXECUTIVE OFFICERS OF PFIZER INC.</strong></p>
      </blockquote>
    </blockquote>
  </blockquote>
</blockquote>
<table border="1" cellspacing="0" cellpadding="0" width="662">
  <tr>
    <td width="187" valign="bottom"><p align="center"><strong>NAME</strong></p></td>
    <td width="294" valign="bottom"><p align="center"><strong>POSITION</strong></p></td>
    <td width="181" valign="bottom"><p align="center"><strong>ADDRESS</strong></p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Ian C. Read</p></td>
    <td width="294" valign="top"><p>Chairman and Chief    Executive Officer</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Albert Bourla <br>
    citizen of Greece</p></td>
    <td width="294" valign="top"><p>Group President, Vaccines,    Oncology and Consumer Healthcare</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Frank A. D&rsquo;Amelio</p></td>
    <td width="294" valign="top"><p>Executive    Vice President, Business Operations and Chief Financial Officer </p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Mikael Dolsten, M.D., Ph.D.
    </p></td>
    <td width="294" valign="top"><p>President,    Worldwide Research and Development </p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Geno J. Germano </p></td>
    <td width="294" valign="top"><p>Group President, Global Innovative    Pharma Business </p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Charles H. Hill </p></td>
    <td width="294" valign="top"><p>Executive Vice President,    Worldwide Human Resources </p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Rady A. Johnson</p></td>
    <td width="294" valign="top"><p>Executive    Vice President, Chief Compliance and Risk Officer</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Douglas M. Lankler</p></td>
    <td width="294" valign="top"><p>Executive    Vice President and General Counsel</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Freda C. Lewis-Hall, M.D.</p></td>
    <td width="294" valign="top"><p>Executive    Vice President, Chief Medical Officer</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Anthony J. Maddaluna</p></td>
    <td width="294" valign="top"><p>Executive Vice President;    President, Pfizer Global Supply</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Laurie J. Olson</p></td>
    <td width="294" valign="top"><p>Executive    Vice President, Strategy, Portfolio and Commercial Operations</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>Sally Susman</p></td>
    <td width="294" valign="top"><p>Executive Vice President,    Corporate Affairs </p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="187" valign="top"><p>John D. Young</p></td>
    <td width="294" valign="top"><p>Group President, Global    Established Pharma Business</p></td>
    <td width="181" valign="top"><p>235 East 42nd St.<br>
      New York, NY 10017</p></td>
  </tr>
</table>
<p>&nbsp;</p>
<p align="center"><br>
</p>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
